MEFENAMIC ACID 250 MG + TRANEXAMIC ACID 500 MG TABLETS are a combination solid dosage formulation containing two active pharmaceutical ingredients at different strengths. The formulation presents an interesting development requirement because the active ingredients contribute different material characteristics and together form a relatively high active load within a single tablet. Product development therefore focuses on material compatibility, controlled powder processing, tablet architecture, dose uniformity, and reproducible finished-product quality. For pharmaceutical companies expanding their combination portfolio, the formulation can be developed as part of a structured PCD Pharma Franchise range supported by appropriate manufacturing and quality systems.
Rather than relying only on compression parameters, successful development begins with understanding how the two active ingredients behave individually and after combination. Particle morphology, bulk density, moisture content, flow properties, compressibility, and compatibility with the selected excipients can all influence the final manufacturing process.
The formulation design starts by defining the quantitative relationship between Mefenamic Acid 250 MG and Tranexamic Acid 500 MG. Since Tranexamic Acid represents a higher proportion of the active load, the excipient system must be designed around the overall tablet weight and the physical characteristics of the combined powder.
Suitable pharmaceutical excipients may include diluents, binders, disintegrants, glidants, lubricants, and other functional materials. Their selection depends on the desired tablet properties and manufacturing technology.
Preformulation studies can examine compatibility between both active ingredients and the proposed excipients. Parameters such as moisture uptake, particle-size distribution, density, and flow behavior provide useful information before scale-up.
The objective is to create a formulation in which both active ingredients remain appropriately distributed without adversely affecting the physical integrity or processing performance of the tablet.
An important part of this formulation is preparing the active materials for consistent processing. Differences in particle size and density between Mefenamic Acid and Tranexamic Acid can influence how the materials behave during blending and transfer.
Material conditioning may involve controlled sieving, milling, pre-blending, or other suitable processing steps. Where necessary, the active ingredients can be incorporated into separate premixes before being combined with the remaining formulation components.
The blending sequence is established during process development. Controlled addition of materials can help minimize localized concentration differences and reduce the possibility of segregation.
Blend evaluation can be performed by collecting samples from predetermined locations. These samples may be assessed for the presence and distribution of both active ingredients using suitable analytical procedures.
Maintaining blend uniformity is particularly important in a combination formulation because the quality of the finished tablet depends on consistent distribution of both components rather than only the overall batch assay.
After establishing suitable powder characteristics, the formulation is evaluated for tablet formation. The selected process may involve direct compression or a granulation-based approach depending on flowability, compressibility, and bulk-density requirements.
If granulation is selected, parameters such as binder concentration, granulation endpoint, drying conditions, residual moisture, and granule-size distribution are controlled. These variables can influence tablet hardness and disintegration behavior.
During compression, tooling dimensions, fill depth, compression force, turret speed, and other machine parameters can be optimized to achieve the desired tablet profile.
In-process inspection may include weight, thickness, hardness, friability, visual appearance, and other physical characteristics. Monitoring these parameters helps maintain tablet-to-tablet consistency throughout the batch.
The final tablet structure should provide sufficient mechanical strength for subsequent dedusting, inspection, packaging, transportation, and routine handling without compromising the intended performance characteristics.
Because the formulation contains two different active pharmaceutical ingredients, finished-product testing requires analytical procedures capable of evaluating each component appropriately. Identification and assay testing can be performed using suitable validated or qualified analytical methods.
Dissolution evaluation provides information about how the active ingredients are released from the tablet under controlled laboratory conditions. The formulation may be assessed for the release behavior of both Mefenamic Acid and Tranexamic Acid according to established product specifications.
Other quality-control parameters can include uniformity-related testing, disintegration, hardness, friability, weight variation, and appearance.
The analytical program should be designed so that the presence of one active ingredient does not interfere with accurate evaluation of the other. Proper method development and system suitability controls support reliable laboratory results.
Batch records combine manufacturing observations with analytical results, providing traceability from raw-material dispensing through finished-product release.
Stability evaluation of MEFENAMIC ACID 250 MG + TRANEXAMIC ACID 500 MG TABLETS considers both active ingredients and the complete formulation matrix. Samples may be stored under defined conditions and evaluated at predetermined intervals.
Testing can monitor assay, degradation-related characteristics, dissolution, appearance, hardness, and other relevant physical or chemical parameters. This helps determine whether the formulation maintains its specified characteristics throughout the proposed storage period.
Packaging development is carried out alongside stability assessment because the primary package can influence protection from moisture, light, and other environmental factors. Blister strips or other suitable pharmaceutical-grade packaging may be selected according to the formulation's requirements.
Packaging materials can be evaluated for compatibility, sealing performance, barrier properties, and physical protection. Finished packs are checked for seal integrity, tablet count, batch details, manufacturing information, expiry information, and labeling accuracy.
For a combination-product portfolio, these controls create a documented pathway from formulation development to commercial packaging and distribution.
The overall development of MEFENAMIC ACID 250 MG + TRANEXAMIC ACID 500 MG TABLETS depends on coordination between formulation science, manufacturing controls, analytical testing, stability evaluation, and packaging operations. Each stage contributes to the consistency of the final pharmaceutical product.
A controlled approach to raw-material qualification, material processing, blend evaluation, compression, finished-product testing, and packaging helps establish reproducible manufacturing performance. Documentation of critical process parameters and quality attributes also supports traceability and batch-to-batch comparison.
For pharmaceutical companies looking to expand their combination formulations, this product can be integrated into a broader PCD Pharma Franchise portfolio through systematic product development and professional packaging. A well-defined quality framework allows the formulation to maintain consistent specifications while supporting organized pharmaceutical manufacturing and portfolio presentation.
Mefenamic Acid 250MG + Tranexamic Acid 500MG Tablets with formulation development, manufacturing, quality testing, stability and packaging details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech